American Diabetes Association

Prevent Blindness Provides Informational Resources to Professionals and the Public for November's Diabetes-related Eye Disease Awareness Month

Retrieved on: 
Wednesday, October 25, 2023
UnitedHealth Group, Social media, Population health, US, American Diabetes Association, Diabetic retinopathy, Prevalence, Health, Mental, Disease, Risk, Eye, Public, Paratriathlon, Potential, Retina, Parent, Mental health, MHS, Yale School of Medicine, Organization, Prediabetes, National Eye Institute, CDC, Centers for Disease Control and Prevention, Vision, VSP Vision Care, Research, JAMA Ophthalmology, Visual impairment, Microsoft PowerPoint, Research to Prevent Blindness, MBA, Database, Johns Hopkins School of Medicine, Associate, Pharmaceutical industry, Ophthalmology, Regeneron Pharmaceuticals, MD, Diabetes

CHICAGO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- A recent study, "Prevalence of Diabetic Retinopathy in the US in 2021," estimated that more than 26 percent of people with diabetes had diabetic retinopathy. Diabetic retinopathy, the most common form of diabetes-related eye disease, is the leading cause of blindness in adults age 20–74, according to the National Eye Institute.

Key Points: 
  • Diabetic retinopathy, the most common form of diabetes-related eye disease, is the leading cause of blindness in adults age 20–74, according to the National Eye Institute .
  • The longer a person has diabetes, the greater the risk for diabetes-related eye disease.
  • Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has declared November as Diabetes-related Eye Disease Awareness Month, providing the public with a variety of helpful tools to prevent unnecessary vision loss from diabetes.
  • Vision Integration Library - The Center for Vision and Population Health at Prevent Blindness offers the free "Vision Integration Library: Vision and Eye Health Resource Center at Prevent Blindness."

GoodRx Announces New Way for Consumers to Access Sanofi’s Lantus for $35 at Over 70,000 Pharmacies Nationwide

Retrieved on: 
Thursday, October 19, 2023
Women, Retail, Men, Pharmaceutical, Insurance, Software, Family, Internet, Consumer, Professional Services, Technology, Medical Supplies, General Health, Diabetes, Health, Apps, Applications, Health Technology, Specialty, Health Insurance, Patient, American Diabetes Association, Walmart, News, SNY, Pharmacy, CVS, Insulin, Pharmaceutical industry, Insulin glargine, Walgreens, Sanofi, GoodRx

Sanofi is taking action and providing Americans who need insulin with the ability to access Lantus in an easy and affordable way, regardless of insurance status.

Key Points: 
  • Sanofi is taking action and providing Americans who need insulin with the ability to access Lantus in an easy and affordable way, regardless of insurance status.
  • We’re proud to collaborate with them on this initiative,” said Dorothy Gemmell, Chief Commercial Officer at GoodRx.
  • Patients can visit GoodRx.com/lantus to access the $35 price coupon, which can be redeemed at any pharmacy that accepts GoodRx, including CVS, Walgreens, and Walmart.
  • This complements other savings programs already offered by Sanofi, including offering Lantus for $35 per month to people without insurance.

Sun Life U.S. awards $350,000 to six local organizations around the nation through Team Up Against Diabetes grant program

Retrieved on: 
Monday, October 23, 2023
American Diabetes Association, Education, Chicago Commons, Black, Ward 7 (Windsor, Ontario), Health, Boston Celtics, Project Power, Sun Life Financial, Diabetes, Organization, Maine Celtics, Prediabetes, Health education, Team-up, 1990–91 Boston Celtics season, Hampton Roads, Risk, Wellness, Medicine, Vegetable, Kansas City Royals, Parent, Insulin, Pharmaceutical industry, Nursing, Dietary supplement

We're pleased to continue this grant program that helps people manage their diabetes and live healthier lives."

Key Points: 
  • We're pleased to continue this grant program that helps people manage their diabetes and live healthier lives."
  • Sun Life's Team Up Against Diabetes grant program was launched in 2016 and has awarded more than $2 million to community organizations in the U.S.
  • The local groups selected for grants provide health and wellness services for diabetes prevention, awareness, education, management and care to communities most vulnerable to diabetes.
  • Globally, Sun Life has given more than $37 million to diabetes causes and health programs around the world.

Englewood Health Appoints Two New Physician Leaders to Roles in Behavioral Health and Health Equity

Retrieved on: 
Thursday, October 19, 2023
American Diabetes Association, Psychiatry, University, Education, Endocrine Society, Health, American Psychiatric Association, Stanford University School of Medicine, MD, Maimonides Medical Center, Endocrinology, Diabetes, Metabolism, Saint Andrew's Society, Traumatic brain injury, Northwell Health, Health equity, Student, Internal medicine, Long Island, Cancer, Addiction medicine, Patient, Diagnosis, Mental health, Hospital, Pharmaceutical industry, Nursing, Medical device, Pharmacy

ENGLEWOOD, N.J., Oct. 19, 2023 /PRNewswire/ -- Englewood Health has appointed two new physician leaders to oversee behavioral health and health equity.

Key Points: 
  • ENGLEWOOD, N.J., Oct. 19, 2023 /PRNewswire/ -- Englewood Health has appointed two new physician leaders to oversee behavioral health and health equity.
  • "We are delighted to welcome Dr. Spariosu as director of behavioral health," says Hillary Cohen, MD, senior vice president for medical affairs at Englewood Health.
  • Under her leadership, Englewood Health will build on its success and further meet the behavioral health needs of our communities."
  • Under her guidance, Englewood Health will implement targeted interventions designed to improve health outcomes and health equity for our communities."

January AI Makes Its Digital Twin Technology Available to Food Industry R&D

Retrieved on: 
Sunday, October 8, 2023
Software, General Health, Hardware, Consumer Electronics, Apps, Applications, Technology, Medical Devices, Artificial Intelligence, Health Technology, Fitness & Nutrition, Biotechnology, Health, Diabetes, Prediabetes, Intelligence, American Diabetes Association, Food industry, Taste, Stock, CGM, Exercise, Sleep, Research, Medical device

Several major food companies are exploring the ways in which artificial intelligence can be used to create specialized nutritious food for specific populations.

Key Points: 
  • Several major food companies are exploring the ways in which artificial intelligence can be used to create specialized nutritious food for specific populations.
  • By utilizing digital twins, January AI aims to help the food industry scale the optimization processes previously achieved by a few companies in collaboration with the American Diabetes Association for thousands, if not millions, of food SKUs.
  • “Our digital twin technology gives food companies an additional level of intelligence beyond what they already employ in their product development process,” said Noosheen Hashemi, CEO of January AI.
  • This allows for virtual product development and optimization before any costly lab work is undertaken.”
    For more information about how companies can utilize January AI’s digital twin technology, head to january.ai .

On/Go for Good, Charitable Foundation, Donates Essential Intrivo COVID-19 Test Solutions to the U.S.-Mexico Border Philanthropy Partnership

Retrieved on: 
Wednesday, October 11, 2023
Pillar, Health, COVID-19, Hospital, Mexican Consulate (Yuma, Arizona), American Diabetes Association, Make-A-Wish Foundation, Ronald McDonald House Charities, BPP, Ventanilla, Good, Make, Software, GO Campaign, International border states of the United States, Social impact, Computer, Pharmaceutical industry

MIAMI, Oct. 11, 2023 /PRNewswire/ -- On/Go for Good, the charitable foundation founded by Intrivo, the leading health technology company that delivers the On/Go digital health suite for a variety of health and wellness related conditions, has made a much needed donation of COVID-19 tests to the U.S.-Mexico Border Philanthropy Partnership (BPP.) The tests are to be used for distribution to the public through the Ventanilla de Salud program at Mexican Consulates throughout the U.S.

Key Points: 
  • Contributions are made in the form of financial support, medical supplies, and technology resources.
  • Our collaboration with the U.S.- Mexico Border Philanthropy Partnership exemplifies our commitment to helping everyone live healthier, happier lives."
  • Andy Carey, Executive Director of the U.S.-Mexico Border Philanthropy Partnership, said, "We are elated to continue to support COVID-19 programming with our partners at On/Go.
  • Recently, On/Go for Good has been recognized by Fierce Healthcare as a 2023 Fierce 50 honoree for Social Impact.

Ascensia Diabetes Care and Senseonics Announce 'The CGM for Real Life' Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes

Retrieved on: 
Monday, October 9, 2023
ADA, NYSE, SENS, Advertising, Statistics, TSE, Safety, Real Life, Diabetes, Himawari (satellites), Webcast, CGM, American Diabetes Association, Comparison of multi-paradigm programming languages, Physician, Attention, Patient, Practitioner, Pharmaceutical industry

PARSIPPANY, N.J., Oct. 9, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have launched a new U.S. advertising and marketing campaign for Eversense® E3 CGM System. 'The CGM for Real Life' campaign is designed to significantly drive awareness of Eversense E3 as a unique CGM option that is ideally suited to supporting the everyday lives of people with diabetes. A sample of the new advertising assets can be found here.

Key Points: 
  • 'The CGM for Real Life' campaign is designed to significantly drive awareness of Eversense E3 as a unique CGM option that is ideally suited to supporting the everyday lives of people with diabetes.
  • Eversense E3 is the longest lasting CGM available, with 6-month sensor wear duration and two sensor insertion and removal procedures per year.
  • The campaign demonstrates how Eversense E3 provides a differentiated CGM option, with unparalleled flexibility and long-term use that allows it to seamlessly integrate into real life.
  • 'The CGM for Real Life' campaign is a coordinated awareness effort delivering information about Eversense E3 directly to U.S. consumers.

On/Go Named 2023 Fierce 50 Social Impact Honoree For Its Charitable Work Via On/Go for Good

Retrieved on: 
Friday, October 6, 2023
Health, COVID-19, Hospital, Make-A-Wish Foundation, American Diabetes Association, Fierce, Organization, Population health, COVID-19 testing, Entrepreneurship, Mental health, Good, Education, The Co Founder, Software, GO Campaign, Social impact, Computer, Nursing, San Francisco Bay Area

Fierce 50 recognizes individuals and organizations that confront pressing health challenges, fostering awareness and education while implementing interventions that have a profound impact on the fabric of health and well-being.

Key Points: 
  • Fierce 50 recognizes individuals and organizations that confront pressing health challenges, fostering awareness and education while implementing interventions that have a profound impact on the fabric of health and well-being.
  • The group of 50 has been honored for leading the charge on crucial social issues.
  • The approach of "doing good by doing well" has benefitted hundreds of millions of people globally.
  • When good people are sometimes unsure and hesitant about how to make a difference - we're inclined to a rapid action-learning-iterations cycle that results in real impact.

American Diabetes Association elevates health technology innovation through inaugural event in Silicon Valley

Retrieved on: 
Tuesday, October 3, 2023
Amputation, Kidney failure, Diabetes, Stroke, Ernst & Young, Paratriathlon, Doctor of Philosophy, Royal Bank of Canada, IT Leader Forum, Silicon, BPM, SAN, American Diabetes Association, Showcase, CPA, Association of British HealthTech Industries, Prediabetes, Nerve, ADA, Family, Medtech, National Board of Health and Welfare (Sweden), Disease, Pharmaceutical industry, Video game

The event begins mid-morning with an Exhibitor Showcase where more than 50 start-ups display their technology or innovation in tabletop presentations.

Key Points: 
  • The event begins mid-morning with an Exhibitor Showcase where more than 50 start-ups display their technology or innovation in tabletop presentations.
  • While most of the companies are Silicon Valley/San Francisco Bay Area startups, the event draws applicants from across the country.
  • "The Leaders Forum HealthTech Showcase is what Silicon Valley is about: innovation, technology and progress.
  • "Nearly half of American adults have diabetes or prediabetes, and the impact on the patient, their family, and our society is profoundly underestimated," she continued.

VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes

Retrieved on: 
Monday, October 2, 2023
Volunteering, Communication, Partnership, American Diabetes Association, European Association for the Study of Diabetes, Research and development, Development, EASD, Regulatory News Service, Congress, Research, Prediabetes, Phase, ADA, Industrial Affairs Committee (Iceland), Pharmaceutical industry, Diabetes

VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes

Key Points: 
  • VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • Valbiotis: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes
    The Phase II/III clinical study REVERSE-IT, carried out with the active substance TOTUM•63, in partnership with Nestlé Health Science, will be presented on October 3, during an oral communication at the congress of the European Association for the Study of Diabetes (EASD) 2023.
  • This communication will detail the protocol of the REVERSE-IT study, against early glycemic disorders, as well as the complete characteristics of the population included (636 volunteers), at the beginning of the study.
  • “The success of the REVERSE-IT study constitutes a breakthrough for a non-drug approach to prediabetes and untreated early stages of type 2 diabetes.